Clinical Trial Detail

NCT ID NCT02283320
Title A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BIND Therapeutics
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Age Groups: adult

No variant requirements are available.